PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
Honeywell Quality Management Review helps manufacturers boost efficiency and quality compliance
ZenBio is a highly regarded science-focused company specializing in biospecimens and related services with scientific expertise
The JV will establish a state-of-the-art manufacturing facility to manufacture fermented animal free protein to cater to the global markets
This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
These accolades highlight our unwavering commitment to maintaining the highest safety standards
The tele-icu services which had a soft launch four months ago have already provided valuable assistance to 250+ patients in some of the remotest villages in India
Sigachi's entry into the coatings market is strategically timed to capitalize on the industry's growth potential
The company recorded sales of Rs. 1,129 crore for the fiscal year ended June 30, 2024,
Rad-Sure blood irradiation indicators are FDA 510 (k) cleared medical devices that offer positive visual verification of irradiation at the minimum specified dose
This is in partnership with Mepro Pharmaceuticals which have successfully developed and commercialised the Albendazole Chewable formulation
These digital initiatives are expected to enhance the accessibility and efficiency of drug safety monitoring and standards compliance
The emergence of new infections in India is a growing concern
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
Subscribe To Our Newsletter & Stay Updated
